{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/candida-oral/prescribing-information/nystatin-suspension/","result":{"pageContext":{"chapter":{"id":"52caf1d3-9e52-581c-aa51-d6c5e0d34239","slug":"nystatin-suspension","fullItemName":"Nystatin suspension","depth":2,"htmlHeader":"<!-- begin field ba282df5-6b1f-4df6-8415-224d584af90b --><h2>Nystatin suspension</h2><!-- end field ba282df5-6b1f-4df6-8415-224d584af90b -->","summary":"","htmlStringContent":"<!-- begin item 81b5db58-66d6-4b36-a136-3bc7bb9b75a0 --><!-- end item 81b5db58-66d6-4b36-a136-3bc7bb9b75a0 -->","topic":{"id":"0f1d88eb-55a0-530e-a259-eb14f0dda14a","topicId":"b0c376a4-6364-437c-b2b0-0b37c1f9457c","topicName":"Candida - oral","slug":"candida-oral","lastRevised":"Last revised in September 2019","chapters":[{"id":"18d6ae12-7e70-5db1-bc04-693d5cb239d6","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"5e30b9ac-9bad-5d72-95a0-522910be9b02","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"a6e1a973-1e09-50e9-884c-3320ada5f64a","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"e89a359d-f797-5ff2-a94a-511199763a4b","slug":"changes","fullItemName":"Changes"},{"id":"e3aa3dcf-265b-5bf3-8920-86af41a82b81","slug":"update","fullItemName":"Update"}]},{"id":"1c10a9c3-b22e-5e15-9f5e-fd1b321eda87","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"2044b7f8-9a22-580a-a6ee-d09f8e57e822","slug":"goals","fullItemName":"Goals"},{"id":"a2a6fc92-6ee5-5340-8de6-99645565cff9","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"3d375136-1f32-5b18-bfaa-072565762749","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"5055e999-d687-5080-a905-6d314ff96a68","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"7974345e-7b16-5e65-be63-f0b8a60779ef","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"19434a87-22cd-57f9-9507-fa3784bc88e9","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"52cafe43-224c-5c66-934b-d40eb1b71de5","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"372003e6-a514-5b66-8e01-c0c4c24fcf84","slug":"definition","fullItemName":"Definition"},{"id":"6209fe71-2228-5859-966c-9dbcca7da121","slug":"causes-risk-factors","fullItemName":"Causes and risk factors"},{"id":"543a3d8a-2699-5ab1-8d60-91f808bddfdf","slug":"prevalence","fullItemName":"Prevalence"},{"id":"f317e3a4-4b69-5c95-9d13-c551a893ac44","slug":"complications","fullItemName":"Complications"},{"id":"a19dd915-bb50-52c5-94e7-3c7f215a0ac3","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"8b32d0b5-0a06-58dc-9e26-cd5930c9b82e","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"e6f234d8-47d7-5740-8739-58962c6c3a1c","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"f276724c-839b-5e50-9ed1-f685c12b1c5a","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"32ef3be0-0861-5c08-932e-c4295def32b8","fullItemName":"Management","slug":"management","subChapters":[{"id":"4dbdf8e9-97b5-54f2-8023-94e3da894f99","slug":"children-not-immunocompromised","fullItemName":"Scenario: Children (not immunocompromised)"},{"id":"462896e2-aa8a-5693-80bc-cb11b1d29ef2","slug":"adults-young-people-not-immunocompromised","fullItemName":"Scenario: Adults and young people (not immunocompromised)"},{"id":"10d79010-5f47-51a1-be04-e6086178a3da","slug":"adults-immunosuppressive-treatment","fullItemName":"Scenario: Adults (immunosuppressive treatment)"},{"id":"13250ef8-0c39-5e07-b367-3b38fab47e57","slug":"adults-hiv-positive","fullItemName":"Scenario: Adults (HIV positive)"}]},{"id":"800e543f-aa34-535b-982f-b67228787534","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"50f16582-74d2-54ab-82c2-4d34b643efbd","slug":"miconazole-oral-gel","fullItemName":"Miconazole oral gel"},{"id":"52caf1d3-9e52-581c-aa51-d6c5e0d34239","slug":"nystatin-suspension","fullItemName":"Nystatin suspension"},{"id":"eaecb9ab-d5ac-5b61-b987-ed97a3b933fd","slug":"fluconazole-oral","fullItemName":"Fluconazole - oral"}]},{"id":"9d6aa898-2416-5c14-92f0-effd8eee476e","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"aefe3a29-b255-5d42-81cf-2ec2c53a1d28","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"f1d318f6-b308-52db-a6ef-c314467ec43f","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"4b0b04f2-6c79-5699-8121-895467604792","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"545d5c41-fb5a-5561-9a76-8cf64fe0b179","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"098d8b0b-527b-57aa-b706-e69ada6b04fd","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"6e055ac7-10af-5a82-b3ff-1d1c789b3c91","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"4e3093df-a561-5cba-84a5-99f5890a58a5","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"800e543f-aa34-535b-982f-b67228787534","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"caefd091-46cd-5117-9251-bc6dd86cf0af","slug":"licensed-doses","fullItemName":"Licensed doses","depth":3,"htmlHeader":"<!-- begin field a81f2bbb-011f-4248-a199-a76000aa999e --><h3>What are the licensed doses?</h3><!-- end field a81f2bbb-011f-4248-a199-a76000aa999e -->","summary":"","htmlStringContent":"<!-- begin item 46673746-cffe-4e9f-b099-a76000aa99f2 --><!-- begin field feb49ed2-a77c-4425-b944-a76000aa999e --><ul><li><strong>Nystatin suspension (100,000 units/mL) is indicated for</strong> <strong>the prevention and treatment of candidal infections of the oral cavity, oesophagus, and intestinal tract.</strong></li><li><strong>The licensed</strong><strong> dose for oral candidiasis is</strong> 1ml (100,000 units) dropped into the mouth four times a day, usually for 7 days.</li><li><strong>Advise that:</strong><ul><li>Nystatin should be taken<strong> </strong>after food or drink.</li><li>The suspension should be kept in contact with the affected areas for as long as possible.</li><li>The treatment should be continued for 48 hours after lesions have resolved.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">BNF 72, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">ABPI Medicines Compendium, 2017</a>]</p><!-- end field feb49ed2-a77c-4425-b944-a76000aa999e --><!-- end item 46673746-cffe-4e9f-b099-a76000aa99f2 -->","subChapters":[]},{"id":"12e8723a-c4d7-5d3d-8cbe-ba3b290359e1","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 5de1b4ac-4146-48f7-a520-a76000ab4123 --><h3>What are the contraindications and cautions?</h3><!-- end field 5de1b4ac-4146-48f7-a520-a76000ab4123 -->","summary":"","htmlStringContent":"<!-- begin item 9752a179-7613-4da0-937c-a76000ab40d2 --><!-- begin field b9e919f5-11f0-45b7-8099-a76000ab4123 --><ul><li><strong>Do not prescribe nystatin suspension to:</strong><ul><li>People with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase-isomaltase insufficiency — nystatin suspension contains sucrose.</li></ul></li><li><strong>Prescribe nystatin suspension with caution to:</strong><ul><li>People on a controlled sodium diet — nystatin suspension contains 0.3 mmol (or 1.3 mg) sodium per 1 ml dose.</li><li>People with diabetes mellitus — nystatin suspension contains sucrose.</li><li>Pregnant women.<ul><li>Absorption of nystatin from the gastrointestinal tract is negligible. However, the manufacturer advises that it should be prescribed during pregnancy only if the potential benefits to be derived outweigh the possible risks involved, as it is not known whether nystatin can cause foetal harm when administered to a pregnant woman or can affect reproductive capacity [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">ABPI Medicines Compendium, 2017</a>].</li></ul></li><li>Breastfeeding women.<ul><li> The manufacturer advises that caution should be exercised when nystatin is prescribed for a breastfeeding woman, as it is not known whether nystatin is excreted in human milk [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">ABPI Medicines Compendium, 2017</a>].</li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">BNF 72, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">ABPI Medicines Compendium, 2017</a>]</p><!-- end field b9e919f5-11f0-45b7-8099-a76000ab4123 --><!-- end item 9752a179-7613-4da0-937c-a76000ab40d2 -->","subChapters":[]},{"id":"ad77a868-331f-5923-bd3e-d71c3aab6881","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field cd6a0d87-cea9-45cd-a331-a76000ab5f83 --><h3>What are the adverse effects?</h3><!-- end field cd6a0d87-cea9-45cd-a331-a76000ab5f83 -->","summary":"","htmlStringContent":"<!-- begin item b120d98f-a21d-4bed-b8f2-a76000ab6012 --><!-- begin field c4436409-fa7c-4add-bc9d-a76000ab5f83 --><ul><li><strong>Nystatin is generally well tolerated by all age groups, even during prolonged use. </strong>However:<ul><li>Nausea has been reported occasionally during treatment. </li><li>Large oral doses of nystatin have occasionally produced diarrhoea, gastrointestinal distress, nausea, and vomiting.</li><li>Rash, including urticaria, has been reported rarely. Steven-Johnson Syndrome has been reported very rarely.</li><li>Hypersensitivity and angio-oedema, including facial oedema, have been reported.</li></ul></li><li><strong>If irritation or sensitization develops, treatment should be discontinued.</strong></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">BNF 72, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">ABPI Medicines Compendium, 2017</a>]</p><!-- end field c4436409-fa7c-4add-bc9d-a76000ab5f83 --><!-- end item b120d98f-a21d-4bed-b8f2-a76000ab6012 -->","subChapters":[]},{"id":"a60811ba-6a4e-5633-9418-1dd735ec813c","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 9f3f5d69-502d-45d3-94c4-a76000abc9dc --><h3>What drug interactions are associated with nystatin suspension?</h3><!-- end field 9f3f5d69-502d-45d3-94c4-a76000abc9dc -->","summary":"","htmlStringContent":"<!-- begin item 10f70cf6-9eed-4ad5-9733-a76000abc8b7 --><!-- begin field d7208bff-a85d-4334-8af9-a76000abc9dc --><ul><li>There are no known drug interactions with nystatin suspension.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">ABPI Medicines Compendium, 2017</a>]</p><!-- end field d7208bff-a85d-4334-8af9-a76000abc9dc --><!-- end item 10f70cf6-9eed-4ad5-9733-a76000abc8b7 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}